iCad Reports Second Quarter Financial Results

iCad Reports Second Quarter Financial Results

<0> For iCADKevin Burns, 937-431-7967orFor iCAD investor relationsLHAAnne Marie Fields, 212-838-3777 x6604orFor iCAD media inquiriesSchwartz MSLHelen Shik, 781-684-0770 </0>

an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and six months ended June 30, 2012.

“Our financial results for the second quarter of 2012 were mixed as we experienced weaker than anticipated revenues, while we continued to make solid progress managing expenses and reducing cash burn,” said Ken Ferry, President and CEO of iCAD.

“Cancer Detection revenues reflect a slowing in the transition from film to digital technology in mammography as the cycle nears completion. We are transitioning our business model to increase our recurring revenue by offering our products on a subscription basis. To that end, we were delighted to launch PowerLook AMP, our next-generation mammography computer-aided detection (CAD) system in July of 2012. This new platform brings to the radiologist a leading-edge set of additional workflow tools such as breast density and tissue and lesion measurements. We recently began to market this upgrade to our U.S. installed base of more than 3,500 systems, and expect that, over time, this system will provide us with a considerable revenue opportunity.

“Therapy revenue was substantially stronger compared to the second quarter of 2011; however, due to a few deals pushing into the third quarter, we were not able to achieve the sequential quarterly revenue growth that we anticipated. We did, however, book two of these orders in early July which has helped to get the third quarter off to a good start. Interest and momentum continues to grow in the Axxent Electronic Brachytherapysystem as evidenced by the number of new controller sales in the first half of 2012 compared to the same period last year, as well as from the significant growth of Intra-Operative Radiation Therapy (IORT) procedures-based consumable sales. Balloon applicator sales, which are used primarily with breast IORT, set a record with 161 units sold in the second quarter and 286 units sold during the first half of 2012. This compares to 61 units for the first half of 2011, representing a nearly five-fold increase in procedure volume.

“In addition, the Centers for Medicare and Medicaid Services, in their 2013 proposed rule assigned a separate payment value for IORT delivery treatment codes. We are quite pleased with this proposed decision and believe this will only add to the pace of adoption of breast IORT.

“We enter the back half of 2012 confident that the progress we have made in the execution of our strategy will be the foundation for iCAD to have a much stronger second half,” concluded Mr. Ferry.

Total revenue for the second quarter of 2012 decreased 11% to $5.9 million from $6.6 million for the second quarter of 2011. The decrease resulted primarily from a decline in Cancer Detection product revenues due to the near completion of the mammography market’s transition from film to digital technology. This decrease was offset by growing sales related to the Axxent Electronic Brachytherapy system, which contributed approximately $1.5 million in revenue, representing a 28% increase compared with the second quarter of 2011.

Cancer Detection revenue includes film, digital mammography, MRI and CT CAD platforms, as well as service and supply revenue from these products. Therapy revenue includes Xoft Axxent Electronic Brachytherapy product sales, as well as the associated service and supply revenue.

: Gross profit for the second quarter of 2012 was $4.2 million, or 70% of revenue, compared with $4.5 million, or 68% of revenue, for the second quarter of 2011.

The Company significantly lowered total operating expenses during the second quarter of 2012 to $6.1 million from $9.8 million for the second quarter of 2011, a decrease of 38%. This decrease is primarily due to on-going cost-saving measures implemented by the Company.

For the second quarter of 2012 the Company posted a net loss of $2.9 million, or $0.05 per share, compared with a net loss of $5.4 million, or $0.10 per share, for the second quarter of 2011.

For the second quarter of 2012 the Company posted a non-GAAP adjusted net loss of $2.7 million, or $0.05 per share, compared with a non-GAAP adjusted net loss of $4.8 million, or $0.09 per share, in the second quarter of 2011.

Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss of $931,000 in the second quarter of 2012, compared with a loss of $3.6 million in the second quarter of 2011.

Total revenue for the six months ended June 30, 2012 was $12.3 million, a decrease of 12%, compared with total revenue of $14.0 million for the six months ended June 30, 2011. The Axxent Electronic Brachytherapy system contributed approximately $3.5 million to revenue in the first six months of 2012, an increase of $1.0 million or 41% compared to the first six months of 2011. Therapy revenue consisted of approximately $2.3 million in product sales and $1.2 million in service and supply revenue.

: Gross margin for the first six months of 2012 was $8.6 million, or 70% of revenue, compared with $9.6 million, or 69% of revenue, for the first six months of 2011.

For the first half of 2012 the Company posted a net loss of $5.2 million, or $0.10 per share, compared with a net loss of $9.7 million, or $0.18 per share, for the first half of 2011.

For the first six months of 2012 the Company posted a non-GAAP adjusted net loss of $5.5 million, or $0.10 per share, compared with a non-GAAP adjusted net loss of $8.3 million, or $0.15 per share, for the first six months of 2011.

Non-GAAP Adjusted EBITDA was a loss of $1.9 million for the first six months of 2012, compared with a loss of $5.9 million for the first six months of 2011.

: As of June 30, 2012, the Company had cash and cash equivalents of $14.3 million, compared with $4.6 million as of December 31, 2011. During the first six months of 2012, net cash used by operations was $4.3 million. In January 2012 the Company entered into a five-year, $15 million debt facility agreement with Deerfield Management Company LP, a leading healthcare investment fund. Under the terms of the agreement, the Company issued a $15 million principal amount of senior secured notes, which included a revenue purchase agreement and warrants.

In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's web site at .

iCAD management will host an investment community conference call on Thursday, August 2, 2012 beginning at 10:00 a.m. Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-510-9834 (domestic) or 617-614-3669 (international) and entering passcode 86742657. The call also will be broadcast live on the Internet at , and .

A replay of the conference call will be accessible two hours after its completion through August 9, 2012 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 47354887. The call will also be archived for 90 days at and .

iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. For more information, call 877-iCADnow, or visit .

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SEC’s website at .

(Unaudited, in thousands, except per share amounts)

The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company's financial results determined in accordance with United States generally accepted accounting principles (GAAP). An explanation of these measures is also included below under the heading "Explanation of Non-GAAP Financial Measures".

While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of the Company's business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP.

The Company reports its financial results in accordance with United States generally accepted accounting principles, or U.S. GAAP (“GAAP”). However, management believes that in order to properly understand the Company's short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company's ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company's ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company's financial and operational performance and comparing this performance to its peers and competitors.

Management defines "Non-GAAP Adjusted EBITDA" as the sum of GAAP net loss before provision for income taxes, acquisition-related expenses, total other (income) expense, stock-based compensation expense, depreciation and amortization, severance, gain on sale, amortization of acquired intangibles, acquisition related, patent litigation and recall costs, contingent consideration, indemnification asset and goodwill impairment charges. Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance.

Management defines "Non-GAAP Adjusted Net Loss" as the sum of GAAP net loss before provision for the gain on sale of asset, severance, transaction, patent litigation and recall costs, contingent consideration, indemnification asset and goodwill impairment charges. Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance.

Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

On occasion in the future, there may be other items, such as significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.

Suggested Articles

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes.